ARKRAY USA Receives FDA Clearance On GLUCOCARD(TM) 01 Blood Glucose Monitoring System

ARKRAY USA, Inc. announced 510(k)
clearance on GLUCOCARD(TM) 01 Blood Glucose Monitoring System.


GLUCOCARD(TM) 01



This new, affordable system requires no coding, displays results in 7
seconds, and requires a tiny 0.3 microliter sample size. GLUCOCARD(TM) 01
is AST approved and has a 360-count test memory with time and date stamp.
It also features a large, easy-to-read display for better viewing of test
results. The GLUCOCARD(TM) 01 is distinguished by its leading edge design
and technology. Recent clinical data showed GLUCOCARD(TM) 01 to be highly
accurate.



"ARKRAY is excited to announce a new addition to our growing line of
GLUCOCARD(TM) blood glucose monitoring systems. The novel GLUCOCARD(TM) 01
system follows the GLUCOCARD(TM) brand image of sleek, compact, and
discreet. The GLUCOCARD(TM) 01 appearance is similar to leading cell phone
designs and unlike other glucose monitors on the market," said Jonathan
Chapman, President of ARKRAY USA, Inc. "We look forward to building off the
GLUCOCARD(TM) 01 technology and launching further systems later this year
that will utilize the identical test strip."



About ARKRAY USA



ARKRAY has been a pioneer for nearly 50 years in the field of automated
analysis from laboratory and point-of-care systems to home use patient
self-testing systems. ARKRAY's primary focus throughout that time has been
diabetes, developing the world's first hand held blood glucose meter (late
1960s) and the world's first HbA1c analyzer (1982). ARKRAY is one of the
few diabetes testing companies in the US market today that undertakes
in-house each step of the development process to bring products to market.
ARKRAY is among the leading medical device companies noted for their
patent-based intellectual property by Patent Board (Wall Street Journal
6/17/08). Worldwide, ARKRAY is the 5th largest blood glucose meter
manufacturer.


ARKRAY USA

arkrayusa